Lyndra Therapeutics
Lyndra Therapeutics, based in Watertown, MA, specializes in developing long-acting oral therapies using its LYNX™ drug delivery platform to enhance patient compliance by reducing dosing frequency.
Series E Funding
Lyndra Therapeutics has successfully raised $101 million in Series E funding as of December 21, 2023. This funding round is a notable milestone for the company, underscoring investor confidence in its innovative approach to developing long-acting oral therapies. The capital will likely support ongoing research and development initiatives, as well as the commercialization of its proprietary technologies.
Long-Acting Oral Therapies
Lyndra Therapeutics is focused on developing long-acting oral therapies that simplify patient medication regimens. By reducing the frequency of dosing, these therapies aim to improve medication adherence and overall patient experience. This approach is particularly beneficial for individuals with chronic conditions, ensuring they receive consistent treatment without the burden of daily medication.
LYNX™ Drug Delivery Platform
The LYNX™ drug delivery platform is a cornerstone of Lyndra Therapeutics' innovation. Designed to transform the patient experience, this platform enables medications to be taken less frequently while maintaining therapeutic efficacy. By leveraging this technology, the company aims to enhance the quality of life for patients through more convenient and effective treatment options.
Product Pipeline
Lyndra Therapeutics has a diverse pipeline of products addressing a range of therapeutic areas including Central Nervous System (CNS) disorders, cardiometabolic diseases, women's health, and infectious diseases. This broad focus aligns with the company's mission to address significant unmet medical needs across various health conditions using its proprietary drug delivery technology.
Location and Manufacturing
Lyndra Therapeutics is headquartered in Watertown, MA, with a custom-built Good Manufacturing Practice (GMP) facility located in Lexington, MA. The GMP facility supports the company's manufacturing needs and ensures compliance with industry standards, facilitating the production of its innovative long-acting therapies.
Oral Weekly Risperidone (LYN-005)
Lyndra Therapeutics is advancing LYN-005, a long-acting oral weekly formulation of Risperidone, aimed at treating schizophrenia. The company is conducting pivotal Phase 3 studies to assess its efficacy and safety. In 2023, data on this innovative therapy were presented at the American Society of Clinical Psychopharmacology Annual Conference, highlighting its potential to improve the treatment landscape for schizophrenia.